SiwenHu-LieskovanMD

Hematologic Oncology, Melanoma

Assistant Professor of Medicine

Dr. Hu-Lieskovan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2008 - 2011
China Medical University ShenyangClass of 1998

PubMed

Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature.
John Marsiglio, Jordan McPherson, Matthew Wahl, Siwen Hu-Lieskovan
Melanoma Research. 2024-12-20
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.
Rachel Woodford, Janet McKeown, Lotte L Hoeijmakers, Johanna Mangana, Florentia Dimitriou
European Journal of Cancer. 2024-11-01
1 citations
Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials.
Muhammad Zaki Hidayatullah Fadlullah, Ching-Nung Lin, Samuel Coleman, Arabella Young, Abdul Rafeh Naqash
The Oncologist. 2024-05-03

Journal Articles

Prognostic Gene Expression Profiling in Cutaneous Melanoma
Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology

Lectures

Heterogeneity of Resistant Mechanisms to PD-1 Checkpoint Inhibitors
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Role of CD4 cells in the complete anti-tumor response to PD1 blockade in a syngeneic murine melanoma model with activated WNT signaling.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progressio...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with Pembrolizumab at SITC 2022November 7th, 2022
Immunotherapy Leads the Way for Melanoma TreatmentDecember 3rd, 2019
Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?March 4th, 2019